Close-up of an the ICR logo on a research centre

Centre for In Vivo Modelling

The Centre for In Vivo Modelling is a newly established research centre within the Division of Cancer Biology at the ICR. Our scientists and clinical researchers use state-of-the-art in vivo models to address fundamental questions in cancer biology, with the ultimate aim of identifying curative treatments. We also serve as a collaborative hub across the ICR and The Royal Marsden, providing cutting-edge expertise in advanced mouse genetics and humanised in vivo models of cancer.

Professor Kamil R Kranc, Chair of Haemato-Oncology, serves as the Centre's Director, while Fabiana Muzzonigro is the Centre Administrator.

 

How we conduct research at this centre

Solid tumours and blood cancers are highly complex ecosystems, with many composed of varying cell types including rare cancer stem cells at the apex of a hierarchical organisation, more differentiated malignant progeny, and a dynamic microenvironment that nurtures tumour growth and survival. At our Centre, we seek to elucidate the fundamental principles that govern this malignant ecosystem. We employ advanced mouse genetics (including barcoding and lineage tracing) and PDX models to dissect how tumour cells function, evolve under selective pressures, evade therapy, and engage with their microenvironment to sustain disease progression. By decoding these intricate cellular and molecular interactions, we aim to identify transformative therapeutic strategies capable of eradicating cancer at its origin - achieving durable remission while preserving normal tissue integrity.

A particular strength of our Centre lies in the generation and application of in vivo models, which are essential for uncovering novel aspects of cancer biology and evaluating emerging therapies. We work in close collaboration with ICR researchers and clinicians at The Royal Marsden to develop patient-derived xenograft (PDX) models of leukaemias and solid tumours by transplanting human cancer tissue into immunocompromised mice. In parallel, we generate and utilise genetically engineered mouse models (GEMMs) to interrogate cancer biology in a physiologically relevant context. By leveraging these sophisticated in vivo systems, the Centre aims to:

  • Uncover new facets of cancer biology in a complex in vivo ecosystem
  • Discover and validate novel therapeutic targets allowing for elimination of cancer stem cells and their malignant progeny in blood cancers and solid tumours
  • Collaborate closely with drug discovery teams at the ICR to develop inhibitors of these targets
  • Evaluate new anti-cancer drugs in pre-clinical in vivo models, paving the way for clinical trials.

In addition to our academic focus, CIVM serves as a collaborative hub across the ICR and The Royal Marsden, providing the ICR community with cutting-edge expertise in advanced mouse genetics and humanised mouse models of cancer.

Join us

We are recruiting two exceptional Group Leaders to join the Division of Cancer Biology and the Centre for In Vivo Modelling (CIVM). This is a unique opportunity to shape the future of cancer biology research, lead innovative programmes, and make discoveries that transform patient outcomes.

These new Group Leaders will investigate fundamental mechanisms of tumour initiation, progression, and treatment resistance, and develop cutting-edge preclinical models to advance understanding of cancer biology. Working in close collaboration across the ICR and The Royal Marsden Hospital, the postholders will translate discovery science into new therapeutic opportunities, contributing to the ICR’s mission to make the discoveries that defeat cancer.

Find out more about the vacancies

Members of this Centre

Pipettes and well plates

In Vivo Modelling core

We provide cutting-edge expertise in advanced mouse genetics and humanized mouse models of cancer.

CIVM Service Core

Other staff:

Driving discovery through collaboration 

At CIVM, our collaborative spirit drives our mission to advance cancer cures. We actively partner with basic science, translational, and clinical research groups across the ICR and The Royal Marsden. Our collaborations also extend beyond, working closely with distinguished academic teams at the Universities of Oxford, Cambridge, Edinburgh, Cardiff, London, Glasgow, and the Francis Crick Institute.

 

News from the Centre

We are recruiting a Group Leader in In Vivo Cancer Modelling. We welcome applications at both the Career Development Faculty and Career Faculty levels. Competitive start up package is available. For further particulars please contact [email protected].

 

 

Current vacancies

Group Leader in In Vivo Cancer Modelling

  • Sutton
  • Cancer Biology
  • From £66,092 per annum
  • Fixed term

The Institute of Cancer Research (ICR) in London seeks to appoint a Group Leader in In Vivo Cancer Modelling to play a pivotal role in advancing our cutting-edge cancer research. The position is based at the newly established Centre for In Vivo Modelling (CIVM), part of the Division of Cancer Biology. We welcome applications at both the Career Development Faculty and Career Faculty levels. Key Requirements The successful candidate will generate and employ state-of-the-art genetic and humanised mouse models of cancer to tackle fundamental and translational questions in haemato-oncology and/or solid tumour oncology. In addition to leading a successful research group, they will expand the CIVM's research capabilities and foster productive collaborations with other groups and centres at the ICR, thus promoting in vivo modelling by integrating it into multidisciplinary projects and initiatives. Applicants must have an internationally recognised track record of leading research in in vivo modelling and advanced mouse genetics, demonstrated by high-quality publications and significant funding success. For more junior candidates, an outstanding track record in cancer research, coupled with a compelling research vision leveraging advanced genetic mouse models and clear potential to secure competitive external funding, is essential. As part of your online application you will be required to upload your full CV which will pre-populate your application form, you will also be asked to attach the following documents and failure to do so will mean your application cannot be considered on this occasion: Lists of major publications, achievements, research grants, distinctions. Research plan (five to six pages outlining your current research interests and research programme for the next 5 years) A PDF of a maximum of five key publications, or other research outputs (e.g. patents) that best demonstrate previous productivity You must also complete the personal statement section of the application form in the format of a covering letter including the names and contact details of three academic referees Department/Directorate Information: Cancer Biology Division Information The ICR is one of the world’s most influential cancer research institutions, with an outstanding track record of achievement dating back more than 100 years. In addition to being one of the UK’s leading higher education institutions for research quality and impact, the ICR is consistently ranked among the world’s most successful for industry collaboration. As a member institution of the University of London, we also provide postgraduate higher education of international distinction. One of the ICR’s key research strategies is to defeat cancer by viewing it as a dynamic ecosystem. We aim to solidify our expertise in state-of-the-art in vivo cancer models to probe these complex cancer ecosystems, discover their underlying biology, and identify new therapeutic targets. The postholder will significantly contribute to driving these strategic priorities. We encourage all applicants to access the job pack attached for more detailed information regarding this role. If you would like to informally discuss this position, please contact Professor Kamil R. Kranc ([email protected]), Director of the Centre for In Vivo Modelling, or Professor Chris Jones ([email protected]), Head of the Division of Cancer Biology at the ICR.

Group Leader in Cancer Stem Cell Biology

  • Sutton
  • Cancer Biology
  • Competitive
  • Permanent

Key Requirements As part of your online application you will be required to upload your full CV which will pre-populate your application form, you will also be asked to attach the following documents and failure to do so will mean your application cannot be considered on this occasion: Lists of major publications, achievements, research grants, distinctions. Research plan (five to six pages outlining your current research interests and research programme for the next 5 years) A PDF of a maximum of five key publications, or other research outputs (e.g. patents) that best demonstrate previous productivity You must also complete the personal statement section of the application form in the format of a covering letter including the names and contact details of three academic referees Department/Directorate Information: Cancer Biology Information The Institute of Cancer Research (ICR) in London seeks to appoint a Group Leader in Cancer Stem Cell Biology to play a pivotal role in advancing our cutting-edge cancer research. The position will be based in newly-refurbished laboratory and office space at our Sutton campus within the Division of Cancer Biology. We welcome applications at both the Career Development Faculty and Career Faculty levels. The ICR is one of the world’s most influential cancer research institutions, with an outstanding track record of achievement dating back more than 100 years. In addition to being one of the UK’s leading higher education institutions for research quality and impact, the ICR is consistently ranked among the world’s most successful for industry collaboration. As a member institution of the University of London, we also provide postgraduate higher education of international distinction. One of the ICR’s key research strategies is to defeat cancer by viewing it as a dynamic ecosystem. We aim to solidify our expertise in the biology of cancer stem cellsaq. The postholder will significantly contribute to understanding the underlying biology of cancer stem cells and how this may be exploited to address key questions in tumour relapse, disease progression and metastasis. The successful candidate will have a compelling research programme focused on cancer stem cell biology in an area which complements existing disease-specific expertise at the ICR / Royal Marsden NHS trust. Possible areas of research include (but are not restricted to) basic mechanisms of self-renewal and pluripotency, regulation of cancer stem cell fate / differentiation, how they remodel the tumour microenvironment into a supportive niche, targeting treatment resistance of cancer stem cells, and the role of CSCs in driving the metastatic cascade. Applicants must have an internationally recognised track record of leading research in cancer stem cell biology, demonstrated by high-quality publications and significant funding success. For more junior candidates, an outstanding postdoctoral track record in cancer research, coupled with a compelling research vision in a strategic area of cancer stem cell biology and clear potential to secure competitive external funding, is essential. If you would like to informally discuss this position, please contact Professor Chris Jones ([email protected]), Head of the Division of Cancer Biology at the ICR.

Data Scientist

  • Sutton
  • Cancer Biology
  • £39,805 - £53,500
  • Fixed term

Under the guidance of Professor Trevor Graham, we are seeking to recruit a Data Scientist to support Data Science research across the ICR. The successful candidate will have particular work on the analysis of spatial data (including multiplex immunohistochemistry, H&Es and spatial transcriptomics) and will be required to stay abreast of new developments in the field and provide training to colleagues. About you The successful candidate must have: A PhD in quantitative subject, or likely to be awarded PhD in the near future. Research experience equivalent to PhD level will be considered. Undergraduate degree, or Masters or equivalent in a quantitative subject. Skills in bioinformatics computing coding, in languages including R, Python and other scripting languages as is appropriate. Experience of using high performance computing (HPC) systems for scientific computing. Experience of computational biology research methodologies pertinent to the role. Department/Directorate Information The Data Science Committee is chaired by Professor Trevor Graham, providing academic leadership of data science at the ICR to maximise the impact of our cancer research, by applying innovative data science and computation tools (in addition to our traditional areas of strength) to tackle the important cancer questions and ensuring infrastructure is considered to enable this. What we offer A dynamic and supportive research environment Access to state-of-the-art facilities and professional development opportunities Collaboration with leading researchers in the field Competitive salary and pension We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Prof Trevor Graham [email protected].

News from the ICR

10/11/25

A new review explains how turning to mathematics is helping researchers decode one of cancer’s most elusive traits: its ability to evolve and adapt.

Understanding how cancers change over time is crucial for the development of effective treatment strategies. If scientists can identify exactly how cancer changes in response to different stimuli, they will be much better placed to tackle treatment resistance and disease progression. In the longer term, this could improve outcomes for patients with all types of cancer.

With the aim of expanding the use of mathematical modelling in this field, the authors have highlighted recent successful projects and considered further ways in which this approach could benefit teams.

The review was written by researchers in the Centre for Evolution and Cancer at The Institute of Cancer Research, London, and it was published in the journal Current Opinion in Cell Biology. The authors are supported by funding from Cancer Research UK and the Medical Research Council.

Understanding the dynamics of cancer evolution

Cancer evolution refers to the processes by which cancer cells change over time, allowing them to survive, grow and resist treatment.

This often occurs through genetic mutations that provide cells with a structural or functional advantage that they pass on to daughter cells. In time, this ‘stronger’ population can represent a significant proportion of the tumour, making it more difficult to treat.

However, non-genetic mechanisms can also shape cancer cell behaviours. In fact, cancer cells sometimes alter their phenotype – their observable morphological and physiological characteristics – in response to a change in environment, without any genetic changes occurring. This phenomenon, known as phenotypic plasticity, has been shown to play an important role in treatment resistance and cancer progression across different cancer types.

At the Centre for Evolution and Cancer, researchers are investigating the combined role of genetic and non-genetic mechanisms in shaping cancer cell behaviour.

A complementary tool

Mathematical modelling is used in various fields, including economics and social and natural sciences. This tool typically presents processes or scenarios in the form of equations, which can provide new insights into complex mechanisms and relationships. It can also serve as a platform for experts to test hypotheses, determine what is likely to happen if certain parameters change and design future experiments.

The review authors believe that mathematical modelling should be used more widely in cancer research to complement traditional experimental approaches. In their work, it facilitates the reconstruction of evolutionary changes over extended periods.

First author Chloé Colson, Postdoctoral Training Fellow at The Institute of Cancer Research (ICR), explained:

“Recent advances in single cell sequencing technologies have enabled us to study cancer cells at higher resolution than ever before. However, most available clinical data only reveal the traits of a cell at a single point in time.

“As cancer evolution is an inherently time-dependent process, we use mathematical models to help us create a more detailed picture of the changes – both genetic and non-genetic – that cancer cells undergo over time, including in response to treatment.”

A choice of models

The review provides a concise yet comprehensive overview of five diverse mathematical approaches that have been, and can be, used to learn about cancer evolution.

Each method has different strengths and limitations. For instance, stochastic branching processes (SBPs) – which simulate the life cycle of individual cells – can help uncover rare mutation events, but they require very detailed data. Meanwhile, ordinary differential equations (ODEs) – which model average population dynamics over time – are effective for predicting tumour growth under treatment, but they do not take individual variability into account.

By selecting the right combination of existing models, researchers can create a powerful toolkit for reconstructing tumour evolution. It is also important that teams continue to develop new, more advanced models to help them address their specific outstanding areas of interest.

Simulating how tumours evolve and respond to treatment will give researchers the knowledge they need to be able to design smarter strategies that anticipate resistance.

One approach currently under investigation is adaptive therapy – a treatment strategy that involves dynamically adjusting drug dosage based on how the tumour responds over time. Rather than eliminating the cancer cells, which often leads to drug-resistant cells dominating, the aim is to maintain a population of drug-sensitive cells that limit the growth of resistant ones.

Other techniques that can be optimised by a full understanding of cancer evolution include combination treatments that target multiple phenotypes at the same time and timed interventions that are delivered when they are most likely to disrupt cancer growth.

“These models aren’t just academic exercises”

For oncologists and researchers, this fusion of maths and medicine could be the key to staying one step ahead of cancer.

Chloé Colson said:

“We’ve put together a comprehensive review focusing on the role of mathematical modelling for studying both genetic and non-genetic modes of cancer cell evolution. We think the review demonstrates the value of mathematical approaches for understanding complex cancer biology.

“It’s exciting to think that as data from single cell sequencing and spatial imaging become more accessible, these models will become even more powerful. The fusion of biology and mathematics is poised to transform how we understand – and ultimately outsmart – cancer.”

Professor Trevor Graham, Professor of Genomics and Evolution and Director of the Centre for Evolution and Cancer at the ICR, and senior author of the review, said:

“These models aren’t just academic exercises; they’re shaping the future of cancer therapy. As we dive deeper into complex biological systems, mathematical modelling is emerging as a vital ally. The models give us a window into what happened in the past and enable us to forecast what the future holds for a disease that refuses to stand still.

“Ultimately, we aim to clarify the mechanisms that allow cancer to develop drug resistance and an increased ability to spread, so we can create more effective and evolution-aware treatment strategies.”

Image credit: Gerd Altmann from Pixabay